Inflammatory mediator pathways in skin

Inflammatory mediator pathways in the skin encompass the complex signaling networks that coordinate the immune response within the cutaneous environment (Source: Nature Reviews Immunology, 2018). These pathways involve a diverse array of mediators, including cytokines, chemokines, and lipid-derived signaling molecules produced by resident cells like keratinocytes and dendritic cells, as well as recruited immune cells (Source: Journal of Investigative Dermatology, 2021). In healthy skin, these pathways facilitate wound healing and defense against pathogens; however, their dysregulation is central to the pathogenesis of chronic inflammatory diseases such as psoriasis and atopic dermatitis (Source: PubMed, PMC7147065). Therapeutic strategies often target specific nodes within these pathways, such as the IL-23/IL-17 axis in psoriasis or the IL-4/IL-13 axis in atopic dermatitis, using monoclonal antibodies or small-molecule inhibitors (Source: StatPearls, 2023). By modulating these specific mediators, clinicians can reduce skin inflammation and improve barrier function while minimizing systemic side effects. Understanding the crosstalk between different inflammatory pathways remains a primary focus for developing next-generation dermatological treatments.

Other names

Cutaneous inflammatory signalingSkin inflammatory cascadesDermatological inflammatory pathwaysCutaneous cytokine networks

Inhibition of specific pro-inflammatory cytokines (e.g., TNF-alpha, IL-17, IL-23, IL-4/13) or intracellular signaling enzymes (e.g., JAK, PDE4) to disrupt the inflammatory cascade in the skin.